For Timber Pharmaceuticals, Inc. (TMBR), analysts’ consensus is at an average recommendation of Hold while assigning it a mean rating of 3. Splitting up the data highlights that, out of 1 analysts covering the stock, none rated the stock as a Sell while none recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas none see the stock as a Buy. None analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.72 in the current quarter.

Timber Pharmaceuticals, Inc. (NYSE:TMBR) trade information

Upright in the green today for gaining 4.63%, in the last five days TMBR remained trading in the green while hitting it’s week-highest on Friday, Jun 19 when the stock touched $2.39-5 price level, adding 5.44% to its value on the day. Timber Pharmaceuticals, Inc.’s shares saw a change of -55.58% in year-to-date performance and have moved -6.61% in past 5-day. Timber Pharmaceuticals, Inc. (NYSE:TMBR) showed a performance of -22.34% in past 30-days. Number of shares sold short was 152.21 Million shares which calculate 0.24 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of $12 to the stock, which implies a rise of 430.97% to its current value. Analysts have been projecting $12 as a low price target for the stock while placing it at a high target of $12. It follows that stock’s current price would jump +430.97% in reaching the projected high whereas dropping to the targeted low would mean a loss of 430.97% for stock’s current value.

Timber Pharmaceuticals, Inc. (TMBR) estimates and forecasts

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 22.7% during past 5 years. In 2020, company’s earnings growth rate is likely to be around 66.4% while estimates for its earnings growth in next 5 years are of 0%